Information Provided By: 
Fly News Breaks for November 10, 2015
JAZZ
Nov 10, 2015 | 08:14 EDT
Leerink analyst Jason Gerberry lowered his price target for Jazz Pharmaceuticals to $187 after the company's Q3 sales missed expectations. Jazz experienced delays in Xyrem refills due to under-capacity at its call center during a period of high call volume driven by the transition of Xyrem to an approved REMS, Gerberry tells investors in a post-earnings research note. He views the call center issues as temporary and keeps an Outperform rating on the stock.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
